Clinical trial
Phase II Prospective Study Evaluating the Role of Directed Cisplatin Based Chemo With Either Vinorelbine or Pemetrexed for the Adj Tx of Early Stage NSCLC in Patients Using Genomic Expression Profiles of Chemo Sensitivity to Guide Therapy
NCT00545948 is registered in ClinicalTrials.gov with Duke University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Prospective Study Evaluating the Role of Directed Cisplatin Based Chemo With Either Vinorelbine or Pemetrexed for the Adj Tx of Early Stage NSCLC in Patients Using Genomic Expression Profiles of Chemo Sensitivity to Guide Therapy
- Lead sponsor
- Duke University
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 31, 2007
- Completion date
- January 31, 2012
- Enrollment
- 31 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.